Navigation Links
Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months

e prior year:


Three Months Ended Nine Months Ended

9/30/2008 9/30/2008

Increase/ Increase/

Principal Products $in millions (Decrease) $in millions (Decrease)

Effexor $982 3% $3,026 7%

Prevnar 717 13% 2,113 12%


Outside U.S. and Canada 697 32% 1,995 35%

Alliance Revenue -

U.S. and Canada 294 23% 904 23%

Nutritionals 408 18% 1,249 19%

Zosyn/Tazocin 305 7% 966 14%

Premarin family 262 (8)% 809 2%

Protonix Family(1) 234 (45)% 621 (57)%

Centrum 186 7% 558 11%

Advil 165 (7)% 502 1%

(1) Protonix family net revenue for the 2008 third quarter and first nine months reflects revenue from both the branded product, $92 and $279, respectively, and Wyeth's own generic version, $142 and $342, respectively.

2008 Third Quarter Results

Overall net revenue increased 4% for the 2008 third quarter, primarily driven by Wyeth's key pharmaceutical franchises, such as ENBREL(R), PREVNAR(R) and Nutritional products, as well as the favorable impact of foreign exchange. Partially offsetting the increases were lower sales of the PROTONIX(R) family.

Selling, general and administrative expenses, excluding certain significant items, decreased 6% for the 2008 third quarter (7% excluding the impact of foreign exchange) versus the 2007 third quarter, primarily due to the realizati

Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Wyeth Wins Philadelphia Diet Drug Trial Involving Claim of PPH
2. Wyeth Announces Increase in Common Stock Dividend
3. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
4. Wyeth Sets Webcast And Conference Call for 2008 Third Quarter Earnings
5. Cyprus and Ireland Add Wyeths 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
6. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
7. Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
8. Wyeths Motion to Overturn Punitive Damages Award Granted by Arkansas Court
9. Wyeth Announces Bernard Poussot Assumes Chairman of the Board Position
10. Wyeth Declares Common and Preferred Stock Dividends
11. Wyeth Pharmaceuticals Announces Organizational Change
Post Your Comments:
(Date:9/15/2014)... Santa Paula, CA (PRWEB) September 15, 2014 ... of long term implantable silicones for the medical ... strength, responsive silicone gel for the implantable medical ... incorporates a unique crosslink technology delivering a silicone ... adhesion. The Dual Matrix technology consists of ...
(Date:9/15/2014)... September 15, 2014 Hydro Dynamics, ... announced today that it will be partnering with ... ( ) for implementing its Shock Wave ... continuous processing. Continuous flow chemistry through process ... pharmaceutical and petrochemical markets for decades. The ...
(Date:9/12/2014)... magnet using an electric field (magnetoelectric memory [MEM] ... next-generation technology for information processing and storage. Multiferroic ... due to the coexistence of electric and magnetic ... spontaneous electric and magnetic polarizations is rare in ... the MEM effect. This article briefly reviews a ...
(Date:9/12/2014)... -- On Thursday, September 11, 2014, the NASDAQ ... Average finished the day 0.12% lower at 17,049.00, and the ... broad based as seven out of ten sectors ended the ... ended the day at 741.83, down 0.33%, while the index ... initiated coverage on the following equities: Exelixis Inc. (NASDAQ: ...
Breaking Biology Technology:Applied Silicone Launches Silicone Gel System with Dual Matrix Technology 2Hydro Dynamics Partners with the Continuous Flow Chemistry Experts of Proteaf Technologies 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5
... Oct. 31, 2011 announces that ... in its catalogue: US ... This report ... Delivery in US$ Million by the following ...
... iBio, Inc. (NYSE AMEX: IBIO ) ... Patent and Trademark Office for US Patent 8,058,511, entitled ... extends iBio,s patent coverage of viral vectors comprising its ... developed by scientists at iBio,s research collaborator, the Fraunhofer ...
... BETHESDA, Md., Oct. 28, 2011 , ... innovator in biotechnology for therapy in diabetes, metabolic syndrome ... services to food, supplement, biotechnology and pharmaceutical companies – ... sell $1.25 million of shares of its common stock ...
Cached Biology Technology:US Intranasal Drug Delivery Industry 2US Intranasal Drug Delivery Industry 3US Intranasal Drug Delivery Industry 4US Intranasal Drug Delivery Industry 5US Intranasal Drug Delivery Industry 6US Intranasal Drug Delivery Industry 7US Intranasal Drug Delivery Industry 8US Intranasal Drug Delivery Industry 9US Intranasal Drug Delivery Industry 10iBio Announces New US Patent for iBioLaunchâ„¢ Technology 2iBio Announces New US Patent for iBioLaunchâ„¢ Technology 3Spherix Announces Closing of Private Placement of $1.25 Million, Discusses Use of Proceeds 2Spherix Announces Closing of Private Placement of $1.25 Million, Discusses Use of Proceeds 3
(Date:9/15/2014)... carbon-halogen bonds are produced naturally across all kingdoms of ... with a broad range of biological activities. The presence ... profound influence on their molecular properties. , ... been to find the late-stage, site-specific incorporation of a ... an sp C-H bond (one of the most inert ...
(Date:9/15/2014)... vision document, released today by the National Academy ... goals, objectives, and strategies for the program and ... next five years (2015-2020). In addition, the ... be funded in 2015, will include exploratory grants, ... , The $500 million, 30-year program to be ...
(Date:9/15/2014)... Research suggests that genes that affect hearing and cognitive ... the ability to understand and perceive rhythm, pitch, timbre, ... authors of a BioEssays article explain that ... within a population, with the majority of individuals having ... a complex trait attributable to several underlying genes, and ...
Breaking Biology News(10 mins):Pitt chemical biologist finds new halogenation enzyme 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4
... about Arctic climate variation during an ancient episode of ... climate variability in the greenhouse world of the Late ... probably would not greatly change the climatic influence associated ... the El Nio Southern Oscillation (ENSO) or ...
... Springer journals Frontiers of Medicine and Protein ... important literature database for medical and biomedical articles, in January. ... publishing partner Higher Education Press. Both journals are part of ... 90 Springer journals. Frontiers in Medicine has a ...
... Ancient stone faces carved into the walls of a well-known ... searching for fossils of extinct giant rats., The team of archaeologists ... tip of East Timor. "Looking up from the cave floor ... on what seemed to be a weathered carving," CSIRO,s Dr Ken ...
Cached Biology News:Arctic climate variation under ancient greenhouse conditions 2Arctic climate variation under ancient greenhouse conditions 3Research literature from China listed in Medline 2Giant rats lead scientists to ancient face carvings 2
RABBIT ANTI HUMAN ATR (aa2122-2380) Immunogen: Human ATR peptide, amino acids 2122-2380...
casein kinase 2, alpha 1 polypeptide, transcript variant 2, mRNA (cDNA clone MGC:15232 IMAGE:4121882), complete cds...
UV LAMP 254 NM 8 WATT, 1 EA. Category: Nucleid Acid Detection Systems....
Biology Products: